Literature DB >> 16328562

Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement.

Luciana Diniz Carneiro Spina1,2, Débora Vieira Soares3, Rosane Resende de Lima Oliveira Brasil3, Priscila Marise Lobo3, Flávia Lúcia Conceição3, Mário Vaisman3.   

Abstract

The aim of this study was to evaluate the effect of 24 months of growth hormone (GH) replacement on glucose metabolism and visceral fat in 17 adults with GH deficiency: 9 men and 8 women; age 40 +/- 1.8 yr. [range 20-61] and body mass index 25 +/- 0.8 Kg/m2. Glucose metabolism was evaluated by a standard oral glucose tolerance test (OGTT), by the homeostatic model assessment (HOMA) insulin resistance index and by the insulin sensitivity index (ISI)-composite derived from the OGTT. Visceral fat was evaluated by CT scan.Twenty-four months of GH replacement induced an increase in the prevalence of abnormal glucose tolerance, with significant progressive increment in 2h-OGTT insulin levels at 3, 12 and 24 months (p = 0.005). Plasma glucose levels and ISI-composite did not alter during the study. HOMA-IR index increased only in the group of patients (n = 8) who had abnormal OGTT at 24 months (p = 0.012). Visceral fat reduced at month 12 and remained decreased until the end of the study (p = 0.009). In conclusion, the present study suggests that adults with GH deficiency after twenty-four months of GH replacement developed abnormal glucose tolerance, probably due to an increase in insulin resistance, associated with higher insulin levels, despite favorable alterations in body composition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16328562     DOI: 10.1007/s11102-005-5065-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  43 in total

1.  Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes.

Authors:  A Katsuki; Y Sumida; E C Gabazza; S Murashima; M Furuta; R Araki-Sasaki; Y Hori; Y Yano; Y Adachi
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

2.  Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience.

Authors:  C M Hwu; C F Kwok; T Y Lai; K C Shih; T S Lee; L C Hsiao; S H Lee; V S Fang; L T Ho
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

3.  Studies on the pathogenesis of diabetes in acromegaly.

Authors:  R Luft; E Cerasi; C A Hamberger
Journal:  Acta Endocrinol (Copenh)       Date:  1967-12

4.  Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.

Authors:  M Emoto; Y Nishizawa; K Maekawa; Y Hiura; H Kanda; T Kawagishi; T Shoji; Y Okuno; H Morii
Journal:  Diabetes Care       Date:  1999-05       Impact factor: 19.112

5.  A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance.

Authors:  B Bülow; E M Erfurth
Journal:  Clin Endocrinol (Oxf)       Date:  1999-01       Impact factor: 3.478

6.  Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults.

Authors:  K A Al-Shoumer; B Page; E Thomas; M Murphy; S A Beshyah; D G Johnston
Journal:  Eur J Endocrinol       Date:  1996-11       Impact factor: 6.664

7.  Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.

Authors:  A Chrisoulidou; S A Beshyah; O Rutherford; T J Spinks; J Mayet; P Kyd; V Anyaoku; A Haida; B Ariff; M Murphy; E Thomas; S Robinson; R Foale; D G Johnston
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

8.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

9.  Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency.

Authors:  S Seminara; G Merello; S Masi; A Filpo; F La Cauza; G D'Onghia; E Martelli; S Loche
Journal:  Clin Endocrinol (Oxf)       Date:  1998-07       Impact factor: 3.478

10.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

Authors:  E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo
Journal:  Diabetes       Date:  1998-10       Impact factor: 9.461

View more
  3 in total

1.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 2.  Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Yingxuan Wang; Guixia Wang
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

3.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.